Clinical Trials Browser

Interventional × canakinumab × Thoracic × Clear all

NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

Phase 2 Active not recruiting

Lung Neoplasms

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Phase 2 Recruiting

Lung Neoplasms

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04905316 2025-06-17

CHORUS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03447769 2024-10-09

Canopy-A

Phase 3 Terminated

1,382 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT03968419 2024-06-20

CANOPY-N

Phase 2 Terminated

88 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03626545 2023-08-21

CANOPY-2

Phase 3 Terminated

245 enrolled 29 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05725343 2023-02-13

CANAL

Phase 3 Terminated

Lung Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms